Nxstage Medical Beats Up on Analysts Yet Again

Just the facts, Fool.

Seth Jayson
Seth Jayson
May 6, 2013 at 12:00AM
Other

Nxstage Medical (Nasdaq: NXTM) reported earnings on May 2. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), Nxstage Medical met expectations on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded. GAAP loss per share shrank.

Gross margins grew, operating margins contracted, net margins expanded.

Revenue details
Nxstage Medical chalked up revenue of $61.6 million. The nine analysts polled by S&P Capital IQ wanted to see revenue of $61.1 million on the same basis. GAAP reported sales were 8.2% higher than the prior-year quarter's $57.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at -$0.08. The eight earnings estimates compiled by S&P Capital IQ predicted -$0.08 per share. GAAP EPS were -$0.08 for Q1 versus -$0.09 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 38.9%, 150 basis points better than the prior-year quarter. Operating margin was -7.4%, 100 basis points worse than the prior-year quarter. Net margin was -8.1%, 90 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)


Related Articles

Looking ahead
Next quarter's average estimate for revenue is $64.2 million. On the bottom line, the average EPS estimate is -$0.07.

Next year's average estimate for revenue is $264.4 million. The average EPS estimate is -$0.28.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 140 members out of 171 rating the stock outperform, and 31 members rating it underperform. Among 45 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 37 give Nxstage Medical a green thumbs-up, and eight give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Nxstage Medical is outperform, with an average price target of $16.59.

Is Nxstage Medical the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.